Copied
 
 
2023, DKK
11.06.2024
Bruttoresultat

34.144'

Primær drift

-75.903'

Årets resultat

-137''

Aktiver

2.498''

Kortfristede aktiver

756''

Egenkapital

458''

Afkastningsgrad

-3 %

Soliditetsgrad

18 %

Likviditetsgrad

242 %

Resultat
11.06.2024
Årsrapport
2023
11.06.2024
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Nettoomsætning1.012.566.000892.580.000932.545.000991.107.000881.616.000812.500.000867.662.000855.745.000800.654.000
Bruttoresultat34.144.00025.164.000161.384.000246.394.000190.774.000121.357.000208.458.000546.474.000467.806.000
Resultat af primær drift-75.903.000-74.809.00096.348.000232.018.000137.995.00090.437.000171.343.000143.018.00092.941.000
Indtægter af kapitalandele (tilknyttede og associerede) 000000000
Finansielle indtægter3.998.000134.0001.144.000758.000035.00033.0001.052.000210.000
Finansieringsomkostninger-53.997.000-14.083.000-29.513.000-26.667.000-25.358.000-18.952.000-27.109.000-8.534.000-9.869.000
Andre finansielle omkostninger000000000
Resultat før skat-162.974.000-113.589.00054.910.000198.463.000106.061.00061.649.000137.861.000131.433.00082.983.000
Resultat-136.701.000-91.376.00037.642.000155.411.00081.301.00045.844.000106.353.000100.073.00063.953.000
Forslag til udbytte000-130.000.000-160.000.0000000
Aktiver
11.06.2024
Årsrapport
2023
11.06.2024
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Kortfristede varebeholdninger273.249.000218.596.000198.750.000160.640.000187.633.000201.949.000151.218.000133.150.000130.483.000
Kortfristede tilgodehavender fra salg og tjenesteydelser 476.970.000340.436.000209.474.000239.846.000171.281.000268.400.000196.465.000217.977.000148.082.000
Likvider5.822.00026.399.00036.428.00062.977.0009.991.00084.553.0004.00056.0001.825.000
Kortfristede aktiver756.041.000585.431.000444.652.000463.463.000368.905.000554.902.000347.687.000351.183.000280.390.000
Immaterielle aktiver og goodwill481.249.000421.824.000372.548.000354.281.000295.837.000255.490.000166.022.000146.084.000131.477.000
Finansielle anlægsaktiver67.663.00065.747.00079.711.00081.818.00084.301.00014.239.00016.660.00020.325.00022.308.000
Materielle aktiver1.193.246.0001.176.473.0001.124.578.0001.098.822.0001.145.198.0001.179.400.0001.097.209.000999.409.000778.623.000
Langfristede aktiver1.742.158.0001.664.044.0001.576.837.0001.534.921.0001.525.336.0001.449.129.0001.279.891.0001.165.818.000932.408.000
Aktiver2.498.199.0002.249.475.0002.021.489.0001.998.384.0001.894.241.0002.004.031.0001.627.578.0001.517.001.0001.212.798.000
Aktiver
11.06.2024
Passiver
11.06.2024
Årsrapport
2023
11.06.2024
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Forslag til udbytte000130.000.000160.000.0000000
Egenkapital458.408.000596.345.000681.404.000770.126.000778.328.000895.989.000770.467.000659.605.000560.874.000
Hensatte forpligtelser125.775.000139.981.000160.726.000150.464.000113.539.00099.777.00084.662.00077.848.00071.822.000
Langfristet gæld til banker000000000
Anden langfristet gæld36.898.00037.195.00036.135.00011.506.0000000
Leverandører af varer og tjenesteydelser101.687.00084.883.00097.042.00061.653.00056.688.000109.684.00076.547.00062.068.00073.556.000
Kortfristede forpligtelser311.787.0001.476.251.0001.142.164.000453.138.000406.174.000427.397.000195.408.000569.174.000382.173.000
Gældsforpligtelser1.914.016.0001.513.149.0001.179.359.0001.077.794.0001.002.374.0001.008.265.000772.449.000779.548.000580.102.000
Forpligtelser1.914.016.0001.513.149.0001.179.359.0001.077.794.0001.002.374.0001.008.265.000772.449.000779.548.000580.102.000
Passiver2.498.199.0002.249.475.0002.021.489.0001.998.384.0001.894.241.0002.004.031.0001.627.578.0001.517.001.0001.212.798.000
Passiver
11.06.2024
Nøgletal
11.06.2024
Årsrapport
2023
11.06.2024
2022
30.06.2023
2021
29.06.2022
2020
16.04.2021
2019
21.04.2020
2018
22.05.2019
2017
26.03.2018
2016
29.03.2017
2015
18.03.2016
Afkastningsgrad -3,0 %-3,3 %4,8 %11,6 %7,3 %4,5 %10,5 %9,4 %7,7 %
Dækningsgrad 3,4 %2,8 %17,3 %24,9 %21,6 %14,9 %24,0 %63,9 %58,4 %
Resultatgrad -13,5 %-10,2 %4,0 %15,7 %9,2 %5,6 %12,3 %11,7 %8,0 %
Varelagerets omsætningshastighed 3,7 4,1 4,7 6,2 4,7 4,0 5,7 6,4 6,1
Egenkapitals-forretning -29,8 %-15,3 %5,5 %20,2 %10,4 %5,1 %13,8 %15,2 %11,4 %
Payout-ratio Na.Na.Na.83,6 %196,8 %Na.Na.Na.Na.
Gældsdæknings-nøgletal -140,6 %-531,2 %326,5 %870,1 %544,2 %477,2 %632,1 %1.675,9 %941,7 %
Soliditestgrad 18,3 %26,5 %33,7 %38,5 %41,1 %44,7 %47,3 %43,5 %46,2 %
Likviditetsgrad 242,5 %39,7 %38,9 %102,3 %90,8 %129,8 %177,9 %61,7 %73,4 %
Resultat
11.06.2024
Gæld
11.06.2024
Årsrapport
11.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 11.06.2024)
Information om virksomhedens regnskabsklasse:The annual report of Fertin Pharma A/S for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to large reporting class C entities.
Beretning
11.06.2024
Dato for ledelsens godkendelse af årsrapporten:2024-05-27
Oplysning om usædvanlige forhold:As per 31 December 2023, the companies liquidity ratio is below 100, which could indicate uncertainties around the companies liquidity. The company’s structural financing is anchored in PMI’s overall financial strategy and structure and hence based on intercompany loans from the PMI-group and funded through the parent company, Claudio Holdco A/S. As a part of this strategy, DKK 1,274 million of the parent companies (Claudio Holdco A/S) short-term intercompany debt has been converted to a long-term intercompany loan as per 1 March 2023. In addition the Group has been granted a DKK 1,900 million short-term intercompany facility to support the continues development of the company, incl. support to the overall PMI strategy. It is Managements assessment that the provided funding is sufficient to support the companies strategic business plans for the coming year.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Fertin Pharma A/S for the financial year 1 January - 31 December 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Business Activities Fertin Pharma A/S (“Fertin Pharma” or the “Company”) is a specialist Contract Development and Manufacturing Organization (“CDMO”) offering innovative, high quality pharmaceutical and nutraceutical products for oral and intra oral delivery. The Company’s current main product formats (“delivery systems”) are chewing gum, lozenges, powders, fast dissolvable tablets, Zapliq® chewables, and Zapliq® chewing gum. Fertin Pharma is the world’s largest independent developer and manufacturer of medicated chewing gum and has over recent years expanded into other specialized solid dosage oral and intra oral delivery systems. The Company strives to develop innovative oral and intra oral delivery systems that offer convenient and pleasurable delivery of active pharmaceutical ingredients (“APIs") and nutraceutical ingredients (“AIs") to patients and consumers. In 2023, the largest category continues to be high quality chewing gum and lozenges systems applied within Nicotine Replacement Therapy (“NRT”) category. Following the current diversification strategy, Fertin Pharma is still utilizing its highly flexible delivery systems to grow business outside the NRT category, applying a wider range of APIs and AIs for OTC pharma and nutraceutical categories. The Company is headquartered in Vejle, Denmark, where it owns and operates US FDA and EU GMP approved R&D and manufacturing facilities. Furthermore, Fertin Pharma owns and operates commercial, R&D, and manufacturing facilities in India and Canada. Business Review and Outlook In 2023 Fertin Pharma has realigned its focus in execution of the planned diversification of the business, aimed at growing the product and customer base across delivery platforms, API’s, and nutraceutical ingredients as well as geographies. During 2023, the business has returned to growth after being challenged in 2022 by delayed effects from COVID 19. Sales have increased across all categories. The NRT category still forms the backbone of the business and has also proven to be the least affected by COVID 19 pandemic, compared to products in other categories more recently introduced to the market. Following PMI’s acquisition of the Claudio Holdco, the Group has been highly engaged in supporting PMI’s strategy towards a smoke free future. These added activities have materially impacted the Fertin Pharma’s cost structure. During 2023 financial results are positively impacted by prices on especially energy normalizing compared to previous years. The Company has continued executing in R&D and CAPEX throughout 2023, supporting the diversification strategy and future growth. Management expects the 2024 growth and profitability to grow and compared to 2023 and the raw materials and energy prices will stabilize on 2023 level with only moderate inflation. As a result, management expects the 2024 result to improve compared to 2023. Revenue expected in the range of DKK 1,200 million to DKK 1,400 million.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK